Allergan

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Global Facial Injectable Market Report 2023: Sector is Expected to Reach $38.6 Billion by 2033 at a CAGR of 10.45% - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 18, 2023
Cosmetics, Retail, Pharmaceutical, Health, Allergan, Region, Chin, FDA, Therapy, Plastic, American Society of Plastic Surgeons, Society, Application, USD, Beauty salon, Pharmaceutical industry

The "Facial Injectable Market, By Type, By Application, By End User and by Region - Global Forecast To 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Facial Injectable Market, By Type, By Application, By End User and by Region - Global Forecast To 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global facial injectable market size was USD 12.95 billion in 2022 and is expected to reach at USD 38.6 billion by 2033 with a CAGR of 10.45% during the forecast period 2023-2033.
  • The increasing acceptance of less invasive surgeries is one of the factors contributing to market growth.
  • However, facial injectable's relative side effects and lack of permanence is expected to hinder the market growth.

Aviceda Therapeutics Appoints Biopharma and Business Senior Executive Patrick Johnson, PhD, to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023
Health, Other Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Macular degeneration, Allergan, Geographic atrophy, Retina, GA, Inflammation, Doctor of Philosophy, MD, Patient, Entrepreneurship, Therapy, Pharmaceutical industry, Aviceda

Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.

Key Points: 
  • Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.
  • “We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Mohamed A. Genead, MD, CEO & President, Co-Founder of Aviceda Therapeutics.
  • Previously, he gained exceptional sell-side and buy-side transactional experience as head of business development for eye care and drug delivery at Allergan.
  • “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”

Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer

Retrieved on: 
Monday, May 1, 2023
Pepperdine University, Employment, University, RSU, Senior, Marketing, House of Medici, TMS, Business, Quality of life, STIM, Pepperdine Graziadio Business School, Business administration, Patient, Zeltiq Aesthetics, Growth, Master of Business Administration, Jan Vansina, Management, Allergan, Neuronetics

“I am delighted to welcome Lisa in this key position in Neuronetics’ strategic journey,” said Keith J. Sullivan, President and CEO of Neuronetics.

Key Points: 
  • “I am delighted to welcome Lisa in this key position in Neuronetics’ strategic journey,” said Keith J. Sullivan, President and CEO of Neuronetics.
  • Prior roles include Vice President of Marketing at Obalon Therapeutics, which went public in 2016, and ZELTIQ Aesthetics.
  • “The opportunity at Neuronetics is tremendous, and I’m excited to do big things that will drive ongoing growth for the Company and our customers,” stated Lisa Metzner-Rosas.
  • The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

Retrieved on: 
Monday, April 17, 2023
Actavis, Roche, Abbott Laboratories, Allergan, Watson, Fairleigh Dickinson University, Global Operations, Trustee, Growth, Management

BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.

Key Points: 
  • BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.
  • Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent.
  • “We are pleased to welcome Rob Stewart to the CorMedix Board,” said Joseph Todisco, Chief Executive Officer of CorMedix.
  • Mr. Stewart has also previously held management roles with Abbott Laboratories, Knoll Pharmaceutical Company, and Hoffmann La Roche, Inc. Mr. Stewart currently serves on the Board of Directors of Cipla Ltd and serves on the Board of Trustees for Fairleigh Dickinson University.

Faces of South Tampa Joins MedSpa Partners

Retrieved on: 
Wednesday, April 12, 2023
MSP, Michelin Guide, Allergan, Botulinum toxin, Partnership, Patient, APRN, Nursing

Located in Tampa Bay, Florida, Faces of South Tampa is widely recognized as one of the most successful medical aesthetics clinics in the United States.

Key Points: 
  • Located in Tampa Bay, Florida, Faces of South Tampa is widely recognized as one of the most successful medical aesthetics clinics in the United States.
  • Operating out of a beautifully restored century-old mansion, Faces of South Tampa combines the historic warmth and charm of South Tampa with the sophistication and energy of a cutting-edge medical aesthetics clinic.
  • From the beginning, Faces of South Tampa has resolutely adhered to a model of impeccable service combined with undeniable, superior results.
  • We are thrilled to have the Faces of South Tampa family join our larger MSP family."

Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors

Retrieved on: 
Wednesday, March 29, 2023
BSE, Partnership, University, Mecum Dealmakers, Certified Public Accountant, Doctor of Philosophy, Boehringer Ingelheim, Wharton School of the University of Pennsylvania, Senior, Acquisition, MD, AbbVie, Patient, Widener University Commonwealth Law School, CPA, Growth, LOS, J.P. Morgan & Co., J. P. Morgan, Management, Nursing, Allergan

LOS ANGELES, March 29, 2023 /PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Henry Gosebruch to its board of directors.

Key Points: 
  • "I first had the great pleasure of working with Henry when we were bringing Skyrizi to AbbVie.
  • Mr. Gosebruch brings extensive industry experience to ACELYRIN, most recently serving as Executive Vice President and Chief Strategy Officer at AbbVie, a global biopharmaceutical company, from 2015 to February 2023.
  • Mr. Gosebruch currently serves as a member of the board of directors at Aptinyx, Inc. and the advisory board of the Life Sciences & Management Program at the University of Pennsylvania.
  • He received a BSE from the Wharton School at the University of Pennsylvania, and is a Certified Public Accountant (CPA) in Illinois.

Wet Age-Related Macular Degeneration - Pipeline Insight, 2023: Comprehensive Analysis on 80+ Upcoming Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023
Health, Pharmaceutical, SEQUOIA, Retina, Biologics license application, Injection, Ranibizumab, Therapy, Laser, DME, RVO, Symantec Endpoint Protection, AMD, Eye, Fluorescein angiography, Clinical trial, NAMD, NDA, Route of administration, Geographic atrophy, Visual impairment, DR, Diabetic retinopathy, Inflammation, AAV, Novartis, IVT, Blood, Route, Administration, Choroid, Discovery, Acquisition, Peripheral vision, Patient, Molecular Partners, Risk, VEGFR, AbbVie, Macular edema, Diagnosis, Paratriathlon, Growth, Cytokine, Visual acuity, News, Macular degeneration, Medical imaging, Pharmaceutical industry, Publishing, Vaccine, Allergan, Wet, Phase

This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape.
  • A detailed picture of the Wet Age-related Macular Degeneration pipeline landscape is provided which includes the disease overview and Wet Age-related Macular Degeneration treatment guidelines.
  • The companies which have their Wet Age-related Macular Degeneration drug candidates in the most advanced stage, i.e.
  • Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.